人参环氧炔醇治疗阿尔茨海默病的作用机制研究

doi:10.3969/j.issn.1004-616x.2025.03.004

Abstract

Abstract: OBJECTIVE： To use network pharmacology analysis together with molecular docking and in vitro cell experiments for evaluating therapeutic potential of ginseng cyclopentadienol (PND) on Alzheimer's disease，and for understanding its protective effect on neurons. METHODS： Targets of PND in the treatment of Alzheimer' s disease were screened based on PharmMapper， GeneCards， STRING and other databases， and a protein interaction network was constructed. Characteristic pathways were identified by GO and KEGG pathway enrichment analysis and then verified by molecular docking technology. An L-glutamate-induced cell injury model was established using human neuroblastoma SH-SY5Y cells. After treatment of these cells with different concentrations of PND (10，20，40 μmol/L)， cell activity was detected by CCK-8 method，and apoptosis was detected by flow cytometry. RESULTS： A PND-core target-characteristic pathway-Alzheimer's disease network was constructed， and the important targets regulated by PND were found to be ALB， AKT1， EGFR， SRC， CASP3， NFKB1， PTGS2， PPARG， etc. Multiple pathways were identified to involve EGFR， C-type lectin receptor signaling，RAS signaling，PI3K-Akt signaling and Alzheimer's disease signaling. The molecular docking results showed that PND had a good regulatory effect on targets such as CYP3A4，APP，and EGFR. Results from the in vitro cell experiments showed that the survival rate of SH-SY5Y cells in the L-glutamate-induced nerve injury model group was reduced，and the cell survival rate in the 20 μmol/L PND treatment group was higher than that in the model group (P<0.01)；the total apoptosis rate of nerve cells in the model group was 45.23%，and the apoptosis rates of cells in the 10，20 and 40 μmol/L PND treatment groups were 41.34%， 36.96% and 21.86% ， respectively， which were lower than those in the model group (P<0.05 or P<0.01). CONCLUSION： PND showed a neuroprotective effect which may be useful for treatment of Alzheimer's disease.

Key words: panaxydol, network pharmacology, Alzheimer's disease, neuroprotection

CLC Number:

R285.5

ZHANG Weijiang, YANG Jie, YU Zhiying, HE Jianghua, XU Wenjuan. Therapeutic potential of panaxydol on Alzheimer's disease[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 196-201.

References

[1] 马传金, 高丽雯, 张小静, 等. CDDO-E6对 L-谷氨酸诱导SH-SY5Y神经细胞损伤的保护作用[J]. 江苏医药, 2016, 42(11): 1218-1221.
[2] PLATT S R. The role of glutamate in central nervous system health and disease: a review[J]. Vet J, 2007, 173(2): 278-286.
[3] STOJANOVIC I R, KOSTIC M, LJUBISAVLJEVIC S. The role of glutamate and its receptors in multiple sclerosis[J]. J Neural Transm, 2014, 121(8): 945-955.
[4] 宋莉. 人参环氧炔醇对人肝癌细胞株HepG2、SMMC-7721的诱导分化作用[D]. 上海: 上海交通大学, 2007.
[5] 蔡锦贤, 荆晶, 陆阳. 天然聚乙炔醇的研究进展[J]. 中草药, 2007, 38(4): 620-623.
[6] NIE B M, YANG L M, FU S L, et al. Protective effect of panaxydol and panaxynol on sodium nitroprusside-induced apoptosis in cortical neurons[J]. Chem Biol Interact, 2006, 160(3): 225-231.
[7] LIU X F, OUYANG S S, YU B, et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach[J]. Nucleic Acids Res, 2010, 38(suppl_2): W609-W614.
[8] WANG X, PAN C X, GONG J Y, et al. Enhancing the enrichment of pharmacophore-based target prediction for the polypharmacological profiles of drugs[J]. J Chem Inf Model, 2016, 56(6): 1175-1183.
[9] WANG X, SHEN Y H, WANG S W, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database[J]. Nucleic Acids Res, 2017, 45(W1): W356-W360.
[10] WANG J C, CHU P Y, CHEN C M, et al. idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach[J]. Nucleic Acids Res, 2012, 40(Web Server issue): W393-W399.
[11] KNOX C, WILSON M, KLINGER C M, et al. DrugBank 6.0: the DrugBank knowledgebase for 2024[J]. Nucleic Acids Res, 2024, 52(D1): D1265-D1275.
[12] BERMAN H, HENRICK K, NAKAMURA H. Announcing the worldwide protein data bank[J]. Nat Struct Biol, 2003, 10(12): 980.
[13] 汪麟双. 参芪益智颗粒治疗阿尔茨海默病的作用机制研究[D]. 北京: 中国中医科学院, 2023.
[14] 吴东霖, 张鼎, 秦红玲, 等. 基于网络药理学与分子对接技术探讨蛇床子治疗阿尔茨海默病的作用机制[J]. 现代药物与临床, 2024, 39(3): 570-577.
[15] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. NFE2L2: PubChem Gene Summary for Gene 4780, NFE2L2- NFE2 like bZIP transcription factor 2(human) [DS/OL]. [2024- 09-27]. https: //pubchem.ncbi.nlm.nih.gov/gene/NFE2L2/human.
[16] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. PubChem Gene Summary for Gene 3320, HSP90AA1-heat shock protein 90 alpha family class A member 1(human) [DS/ OL]. [2024-09-27]. https: //pubchem.ncbi.nlm.nih.gov/gene/ HSP90AA1/human.
[17] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. PubChem Gene Summary for Gene 351, APP-amyloid beta precursor protein (human) [DS/OL]. [2024-09-27]. https: // pubchem.ncbi.nlm.nih.gov/gene/APP/human.
[18] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. PubChem Pathway Summary for Pathway SMP0063784, Ras Signaling Pathway[DS/OL]. [2024-09-27].https: //pubchem. ncbi.nlm.nih.gov/pathway/PathBank: SMP0063784.
[19] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. PubChem Pathway Summary for Pathway WP4806, EGFR tyrosine kinase inhibitor resistance [DS/OL]. [2024-09-27]. https: //pubchem.ncbi.nlm.nih.gov/pathway/WikiPathways: WP4806.
[20] GUO L C, SONG L, WANG Z J, et al. Panaxydol inhibits the proliferation and induces the differentiation of human hepatocarcinoma cell line HepG2[J]. Chem Biol Interact, 2009, 181(1): 138-143.
[21] ZHU H, WANG W J, DING W L, et al. Effect of panaxydol on hypoxia-induced cell death and expression and secretion of neurotrophic factors (NTFs) in hypoxic primary cultured Schwann cells[J]. Chem Biol Interact, 2008, 174(1): 44-50.

Therapeutic potential of panaxydol on Alzheimer's disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	LI Mei, LI Jianhua, LIU Huan, WANG Zhipeng, GAO Jie, YUAN Hui, SUN Ge. Medication pattern and mechanism of action of traditional Chinese medicine for the treatment of radiation-induced lung injury [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 275-280.
[2]	LIU Shibu, ZHENG Jifan, ZHANG Li, MA Libo, DUO Hui, LIU Mengqi. Network pharmacology-based prediction of Pueraria lobata for treating liver injury [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 118-123.
[3]	DAI Yuxin, LIANG Lichun, PENG Linqian, MENG Fanqi, HAN Xianfeng, ZHANG Yue, YANG Yu, SHANG Yu. Protective effects of oleanolic acid on B lymphocyte injury and exploring its mechanism base on network pharmacology [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 48-52.
[4]	CHENG Yanye, XI Wanwan, MAO Xueyang, WEI Tianyi, HU Hairui, LI Zhigang. A network pharmacologymolecular docking study on mechanisms of Zhenqi Fuzheng granules on colorectal cancerrelated fatigue [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 335-343.
[5]	YU Yuehua, LIANG Huanxi, XIN Yumeng, SUN Zhenxiao. Investigations on anti-gastric cancer effects of licorice and dried ginger decoction [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 219-226.
[6]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.